Literature DB >> 29242112

BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.

Sarah A Holstein1, Hervé Avet-Loiseau2, Theresa Hahn3, Christine M Ho3, Jens G Lohr4, Nikhil C Munshi4, Bruno Paiva5, Marcelo C Pasquini6, Joseph D Tario3, Saad Z Usmani7, Paul K Wallace3, Katja Weisel8, Philip L McCarthy3.   

Abstract

The Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 1, 2016 at the American Society of Hematology meeting to discuss the emerging data and technologies for minimal residual disease assessment and immune profiling in myeloma. Particular emphasis was placed on developing strategies to incorporate these techniques into clinical trial design. This document reviews the literature, summarizes the topics discussed in the workshop, and provides recommendations for integration of these techniques into future clinical trial design.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immune profiling; Minimal residual disease; Multiple myeloma, autologous stem cell transplant

Mesh：

Year:  2017        PMID： 29242112      PMCID： PMC5902638          DOI： 10.1016/j.bbmt.2017.12.774

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


  47 in total

1.  Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.

Authors:  Bruno Paiva; María Victoria Mateos; Luis Ignacio Sanchez-Abarca; Noemi Puig; María-Belén Vidriales; Lucía López-Corral; Luis A Corchete; Miguel T Hernandez; Joan Bargay; Felipe de Arriba; Javier de la Rubia; Ana-Isabel Teruel; Pilar Giraldo; Laura Rosiñol; Felipe Prosper; Albert Oriol; José Hernández; Graça Esteves; Juan José Lahuerta; Joan Bladé; Jose Antonio Perez-Simon; Jesús F San Miguel
Journal:  Blood       Date:  2015-12-14       Impact factor: 22.113

2.  Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.

Authors:  Murielle Roussel; Valérie Lauwers-Cances; Nelly Robillard; Cyrille Hulin; Xavier Leleu; Lotfi Benboubker; Gérald Marit; Philippe Moreau; Brigitte Pegourie; Denis Caillot; Christophe Fruchart; Anne-Marie Stoppa; Catherine Gentil; Soraya Wuilleme; Anne Huynh; Benjamin Hebraud; Jill Corre; Marie-Lorraine Chretien; Thierry Facon; Hervé Avet-Loiseau; Michel Attal
Journal:  J Clin Oncol       Date:  2014-07-14       Impact factor: 44.544

3.  Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma.

Authors:  Jessica Rueff; Michael Medinger; Dominik Heim; Jakob Passweg; Martin Stern
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-13       Impact factor: 5.742

4.  Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies.

Authors:  J F San Miguel; M González; A Gascón; M J Moro; J M Hernández; F Ortega; R Jiménez; L Guerras; M Romero; F Casanova
Journal:  Br J Haematol       Date:  1992-03       Impact factor: 6.998

5.  MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods.

Authors:  Mikhail Roshal; Juan A Flores-Montero; Qi Gao; Maesa Koeber; Jessica Wardrope; Brian G M Durie; Ahmet Dogan; Alberto Orfao; Ola Landgren
Journal:  Blood Adv       Date:  2017-05-03

6.  Host-related immunodeficiency in the development of multiple myeloma.

Authors:  Talib Dosani; Sham Mailankody; Neha Korde; Elisabet Manasanch; Manisha Bhutani; Nishant Tageja; Mark Roschewski; Mary Kwok; Dickran Kazandjian; Rene Costello; Debra Burton; Yong Zhang; David Liewehr; Seth M Steinberg; Irina Maric; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2017-08-09

7.  Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.

Authors:  Rajshekhar Chakraborty; Eli Muchtar; Shaji K Kumar; Dragan Jevremovic; Francis K Buadi; David Dingli; Angela Dispenzieri; Suzanne R Hayman; William J Hogan; Prashant Kapoor; Martha Q Lacy; Nelson Leung; Morie A Gertz
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-20       Impact factor: 5.742

8.  Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.

Authors:  M Ladetto; M Brüggemann; L Monitillo; S Ferrero; F Pepin; D Drandi; D Barbero; A Palumbo; R Passera; M Boccadoro; M Ritgen; N Gökbuget; J Zheng; V Carlton; H Trautmann; M Faham; C Pott
Journal:  Leukemia       Date:  2013-12-17       Impact factor: 11.528

9.  Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.

Authors:  Nikhil C Munshi; Herve Avet-Loiseau; Andy C Rawstron; Roger G Owen; J Anthony Child; Anjan Thakurta; Paul Sherrington; Mehmet Kemal Samur; Anna Georgieva; Kenneth C Anderson; Walter M Gregory
Journal:  JAMA Oncol       Date:  2017-01-01       Impact factor: 31.777

10.  Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.

Authors:  Stefania Oliva; Manuela Gambella; Milena Gilestro; Vittorio Emanuele Muccio; Francesca Gay; Daniela Drandi; Simone Ferrero; Roberto Passera; Chiara Pautasso; Annalisa Bernardini; Mariella Genuardi; Francesca Patriarca; Elona Saraci; Maria Teresa Petrucci; Norbert Pescosta; Anna Marina Liberati; Tommaso Caravita; Concetta Conticello; Alberto Rocci; Pellegrino Musto; Mario Boccadoro; Antonio Palumbo; Paola Omedè
Journal:  Oncotarget       Date:  2017-01-24
View more
  11 in total

1.  Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.

Authors:  Sarah A Holstein; Vera J Suman; Kouros Owzar; Katelyn Santo; Don M Benson; Thomas C Shea; Thomas Martin; Margarida Silverman; Luis Isola; Ravi Vij; Bruce D Cheson; Charles Linker; Kenneth C Anderson; Paul G Richardson; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2020-04-20       Impact factor: 5.742

Review 2.  Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?

Authors:  Shalin Kothari; Jens Hillengass; Philip L McCarthy; Sarah A Holstein
Journal:  Curr Hematol Malig Rep       Date:  2019-02       Impact factor: 3.952

3.  A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.

Authors:  Nikhil C Munshi; Herve Avet-Loiseau; Kenneth C Anderson; Paola Neri; Bruno Paiva; Mehmet Samur; Meletios Dimopoulos; Margarita Kulakova; Annette Lam; Mahmoud Hashim; Jianming He; Bart Heeg; Jon Ukropec; Jessica Vermeulen; Sarah Cote; Nizar Bahlis
Journal:  Blood Adv       Date:  2020-12-08

4.  Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.

Authors:  Sarah A Holstein; Fotis Asimakopoulos; Abdel Kareem Azab; Giada Bianchi; Manisha Bhutani; Leslie A Crews; Tom Cupedo; Hannah Giles; Sarah Gooding; Jens Hillengass; Lukas John; Shari Kaiser; Lydia Lee; Kylee Maclachlan; Marcelo C Pasquini; Flavia Pichiorri; Nina Shah; Monica Shokeen; Brian R Shy; Eric L Smith; Raluca Verona; Saad Z Usmani; Philip L McCarthy
Journal:  Transplant Cell Ther       Date:  2022-05-21

Review 5.  Update on the role of lenalidomide in patients with multiple myeloma.

Authors:  Sarah A Holstein; Vera J Suman; Philip L McCarthy
Journal:  Ther Adv Hematol       Date:  2018-05-26

Review 6.  Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Authors:  Sarah A Holstein; Zaid Al-Kadhimi; Luciano J Costa; Theresa Hahn; Parameswaran Hari; Jens Hillengass; Allison Jacob; Nikhil C Munshi; Stefania Oliva; Marcelo C Pasquini; Qian Shi; Edward A Stadtmauer; Stephanie L Waldvogel; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-14       Impact factor: 5.742

7.  Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma.

Authors:  Dilan A Patel; Ragisha Gopalakrishnan; Brian G Engelhardt; Evonne McArthur; Salyka Sengsayadeth; Katie A Culos; Michael Byrne; Stacey Goodman; Bipin N Savani; Wichai Chinratanalab; Madan Jagasia; Claudio A Mosse; Robert F Cornell; Adetola A Kassim
Journal:  Bone Marrow Transplant       Date:  2020-01-28       Impact factor: 5.483

Review 8.  Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Authors:  Sarah A Holstein; Alan Howard; David Avigan; Manisha Bhutani; Adam D Cohen; Luciano J Costa; Madhav V Dhodapkar; Francesca Gay; Nicole Gormley; Damian J Green; Jens Hillengass; Neha Korde; Zihai Li; Sham Mailankody; Paola Neri; Samir Parekh; Marcelo C Pasquini; Noemi Puig; G David Roodman; Mehmet Kemal Samur; Nina Shah; Urvi A Shah; Qian Shi; Andrew Spencer; Vera J Suman; Saad Z Usmani; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2020-06-24       Impact factor: 5.742

Review 9.  The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.

Authors:  Sarah A Holstein; Nizar Bahlis; P Leif Bergsagel; Manisha Bhutani; Niccolo Bolli; Carrie Brownstein; Pierre Demolis; David Foureau; Francesca Gay; Irene M Ghobrial; Nicole Gormley; Jens Hillengass; Martin Kaiser; Marcela V Maus; J Joseph Melenhorst; Maximilian Merz; Michael O Dwyer; Bruno Paiva; Marcelo C Pasquini; Nina Shah; Sandy W Wong; Saad Z Usmani; Philip L McCarthy
Journal:  Transplant Cell Ther       Date:  2021-06-06

Review 10.  Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.

Authors:  Liu Zhaoyun; Fu Rong
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.